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Abstract
We describe a case of cerebral aspergillosis which was
successfully treated with a combination of caspofungin and
voriconazole. The patient remains in remission 18 months
after stopping antifungal treatment. We discuss primary and
salvage therapy of invasive aspergillosis with focus on cerebral
involvement. Since historical data showed a fatal outcome in
most cases, amphotericin B does not cross the blood brain
barrier while voriconazole does, we chose a combination of
voriconazole plus caspofungin as primary therapy.
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Introduction
Invasive Aspergillosis (IA) is a serious infectious com-
plication in patients with bone marrow transplantation,
haematological malignancies and after solid organ trans-
plantation. Immunocompromised individuals due to
burns, cancer, immunosuppressive therapy, especially
corticosteroids are also at high risk.
IA remains an important cause of morbidity and
mortality despite therapeutic interventions in this patient
population. Cerebral Aspergillosis (CA) accounts for
about 10% of all cases of IA [1]. The outcome of CA is
dismal with mortality rates exceeding 90% [2]. Historically
standard treatment was amphotericin B deoxycholate,
which could be replaced by lipid-based preparations of
amphotericin B in cases of toxicity or major side effects [3].
Voriconazole, a new broad spectrum triazole showed
promising clinical responses in patients with pulmonary or
tracheobronchial IA [4]. Since 2002, voriconazole is first
line therapy of IA [5]. Caspofungin, a novel echinocandin,
is a promising drug for salvage therapy in patients with IA
whose disease is refractory to or who are intolerant to
conventional Amphotericin B [6]. Whether these novel
agents could be used in combination with or in addition to
conventional or liposomal amphotericin B, needs to be
determined.
Case Report
A 43-year-old caucasian cook was treated in a referral hospital
with oral steroids for an acute steatohepatitis in a cirrhotic liver
due to alcohol consumption and being overweight. One month
later he developed ascites. After 2 months, he was referred to the
emergency room in a coma. No metabolic alteration was found,
although hepatic encephalopathy was not excluded by an EEG.
A contrast-enhanced brain CT scan found multiple supra- and
infratentorial ring-enhanced lesions suspicious for abscesses. In
addition, a lesion in the right upper lung lobe was detected. The
largest lesion in the cerebellum was neurosurgically removed and
pathological examination showed septated hyphae. Cultures for
bacteria and fungi remained negative. Broad spectrum fungal
PCR in the surgically removed specimen identified Aspergillus
fumigatus as the causative agent for the abcesses and a diagnosis
of IA with brain abscesses was made [7]. The primary focus was
most likely the lung lesion, although this suggestion was not
proved by invasive procedures. Liver cirrhosis in Child Pugh
Score C and the high dose steroid treatment for 2 months were
identified as potential risk factors.
Combination therapy with caspofungin, 50 mg (after a sin-
gle loading dose of 70 mg) intravenous and voriconazole, 50 mg
twice daily, orally, was started. The voriconazole dose was
empirically reduced because of the decompensated liver cirrho-
sis. The patient’s condition improved within days and he suffered
no side effects. He could be discharged after two and a half
weeks without neurologic sequelae. After 1 month of combina-
tion treatment, he experienced an epileptic seizure, even though
CT scans showed smaller brain lesions and no edema. The eti-
ology of this seizure remained unclear. After starting antiepi-
leptic treatment with phenytoin, no additional seizure occurred.
Liver function improved successively to a Child Pugh score A.
Therefore we increased the voriconazole dosage step by step
under close monitoring of the drug level to finally 200 mg twice a
day. After 8 months of taking this combination therapy (caspo-
fungin 50 mg intravenous once a day and voriconazole 200 mg
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twice a day), a brain MRI showed two small residual supraten-
torial lesions of 6 mm and 8 mm, respectively and a defect after
surgery, in the cerebellum. On CT scan, no ring enhancement
was observed. The lesions were therefore considered to be non
vital and caspofungin was stopped. Voriconazole was continued
for an additional 16 months (2 years in total). During an
18 months follow up after stopping voriconazole, the patient did
well and started a second education as a nutrition consultant.
One year after stopping the anti-epileptic drugs and with a
normal EEG, the neurologist allowed him to drive a car again.
Liver function remains stable with an INR of 1.3 and an albumin
of 36 g/l resulting in a Child Pugh score A.
The costs for the two anti-fungals amounted to approxi-
mately 230,000 Euros. The patient’s medical insurance denied
coverage arguing, that combination treatment of caspofungin/
voriconazole is still experimental and we should have been using
amphotericin B initially. The case went to court and finally the
insurance company had to pay for the cost of both drugs.
Discussion
We believe that fatal outcome of cerebral IA can be
avoided in the era of new antifungals. Successful treat-
ment of CA with voriconazole was first reported in 1997
in a patient with acute leukaemia [8]. Selected cases of
CA treated with voriconazole in children [9] and adults
[10] were reported. In cases of pulmonary aspergillosis
voriconazole usage brought a favorable outcome after
failure of amphotericin B [11]. Limited efficacy of
amphotericin B and itroconazole in patients with CA is
explained by their poor penetration into cerebrospinal
fluid (CSF). High drug concentrations of voriconazole in
CSF of guinea pigs and immunocompromised patients
have been reported [12], which may explain favourable
outcome of CA in patients treated with voriconazole.
Caspofungin is an effective, yet less toxic, alternative
to amphotericin B for the treatment of invasive candidi-
asis [13]. In combination with liposomal amphotericin B,
caspofungin promises encouraging outcome as primary or
salvage therapy against IA in high-risk patients with
haematologic malignancies [14]. The potential benefit of
caspofungin in treating central nervous system infection
due to Aspergillus spp. was demonstrated in a patient with
a brain abscess due to aspergillus, who was successfully
treated with caspofungin monotherapy after developing
nephrotoxicity under treatment for 13 days with ampho-
tericin B [15].
Because of different mechanisms of action, the ab-
sence of cross-toxicity and by enhancing each others
efficacy, the combination of caspofungin and voriconazole
could be a promising alternative. Laboratory findings [16]
and studies in animal models [17] confirmed a synergic
interaction between these two agents. The first case of a
successful treatment of CA with caspofungin/voriconazole
was described in 2003 after failure of amphotericin B
based standard treatment [18]. One small case serie (five
patients) with favorable results was published in abstract
form [19].
Our case shows an excellent outcome with complete
recovery even 18 months after stopping the antifungal
drugs. Because the mortality of CA approaches 100%, we
started our patient directly on the combination therapy of
caspofungin/voriconazole avoiding the mostly unsuccess-
ful use of amphotericin B with its poor penetration into
the CSF. This is supported by the data of Marr et al. [20].
In their retrospective evaluation of patients with IA after
failing amphotericin B, the combination of caspofungin/
voriconazole showed a significant survival benefit after
3 months compared to voriconazole monotherapy.
In our case, voriconazole was initially very low dosed.
This empirical reduction gives us some doubts about the
therapeutic effect at the very beginning of this case and
underlines the importance of administration of the syn-
ergistic caspofungin.
Therefore, in cases of IA with cerebral involvement,
the combination therapy of caspofungin and voriconazole
might be an option. Further trials are needed to determine
its efficacy and to provide data about penetration into
CSF.
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